James Edgemond Sells 10,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $578.58, for a total transaction of $5,785,800.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,921,276.08. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

James Edgemond also recently made the following trade(s):

• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $573.03, for a total transaction of $5,730,300.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $576.93, for a total value of $5,769,300.00.
• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.61, for a total value of $5,726,100.00.
• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $568.83, for a total value of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The shares were sold at an average price of $575.85, for a total value of $209,609.40.
• On Thursday, April 23rd, James Edgemond sold 9,636 shares of United Therapeutics stock. The shares were sold at an average price of $572.21, for a total value of $5,513,815.56.
• On Monday, April 20th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.86, for a total value of $5,778,600.00.
• On Thursday, April 16th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $577.18, for a total value of $5,771,800.00.
• On Monday, April 13th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.88, for a total transaction of $5,748,800.00.
• On Thursday, April 9th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $577.89, for a total transaction of $5,778,900.00.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $581.74 on Wednesday. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The company has a 50-day moving average of $553.65 and a 200 day moving average of $504.46. The firm has a market cap of $24.69 billion, a PE ratio of 21.47, a price-to-earnings-growth ratio of 1.80 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same period last year, the company earned $6.63 earnings per share. The firm’s revenue was down 1.6% compared to the same quarter last year. Sell-side analysts anticipate that United Therapeutics Corporation will post 27.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on UTHR. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. HC Wainwright increased their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Cantor Fitzgerald increased their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, March 12th. Bank of America increased their price objective on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Finally, UBS Group increased their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently bought and sold shares of UTHR. Wellington Management Group LLP increased its stake in shares of United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after acquiring an additional 1,042,711 shares during the period. Darwin Global Management Ltd. purchased a new position in shares of United Therapeutics during the 3rd quarter valued at about $317,617,000. Norges Bank purchased a new position in shares of United Therapeutics during the 4th quarter valued at about $293,418,000. Avoro Capital Advisors LLC raised its stake in shares of United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after buying an additional 383,838 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock valued at $387,801,000 after buying an additional 341,383 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics presented new data from TETON-1, ADVANCE OUTCOMES, and additional research in pulmonary hypertension and pulmonary fibrosis at ATS 2026, which could support the company’s long-term pipeline outlook. Article link
• Neutral Sentiment: Analysts remain broadly constructive, with several recent price target increases and a consensus “Moderate Buy” rating, suggesting the stock still has support from Wall Street despite recent volatility.
• Negative Sentiment: CEO Martine A. Rothblatt sold 9,500 shares, reducing her stake by 19%, and CFO James Edgemond sold 10,000 shares, cutting his holdings by 34.6%. Insider selling can weigh on sentiment because investors may read it as management taking profits after the stock’s strong run. CEO filing CFO filing
• Negative Sentiment: The company also recently reported weaker-than-expected quarterly results, missing on both earnings and revenue, which may still be pressuring valuation even after the stock’s rebound.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.